Abstract:Background: Corneal neovascularization (NV) is a process of abnormal vessel growth into the transparent cornea from the limbus and can disturb the light passing through the cornea, resulting in vision loss or even blindness. The use of nanomedicine as an effective therapeutic formulation in ophthalmology has led to higher drug bioavailability and a slow drug release rate. In this research, we designed and explored the feasibility of a new nanomedicine, gp91 ds-tat (gp91) peptide-encapsulated gelatin nanoparticles (GNP-gp91), for inhibiting corneal angiogenesis. Methods: GNP-gp91 were prepared by a two-step desolvation method. The characterization and cytocompatibility of GNP-gp91 were analyzed. The inhibition effect of GNP-gp91 on HUVEC cell migration and tube formation was observed by an inverted microscope. The drug retention test in mouse cornea was observed by in vivo imaging system, fluorescence microscope, and DAPI/TAMRA staining. Finally, the therapeutic efficacy and evaluation of neovascularization-related factors were conducted through the in vivo corneal NV mice model via topical delivery. Results: The prepared GNP-gp91 had a nano-scale diameter (550.6 nm) with positive charge (21.7 mV) slow-release behavior (25%, 240hr). In vitro test revealed that GNP-gp91 enhanced the inhibition of cell migration and tube formation capacity via higher internalization of HUVEC. Topical administration (eyedrops) of the GNP-gp91 significantly prolongs the retention time (46%, 20 min) in the mouse cornea. In chemically burned corneal neovascularization models, corneal vessel area with a significant reduction in GNP-gp91 group (7.89%) was revealed when compared with PBS (33.99%) and gp91 (19.67%) treated groups via every two days dosing. Moreover, GNP-gp91 significantly reduced the concentration of Nox2, VEGF and MMP9 in NV's cornea. Conclusion: The nanomedicine, GNP-gp91, was successfully synthesized for ophthalmological application. These data suggest that GNP-gp91 contained eyedrops that not only have a longer retention time on the cornea but also can treat mice corneal NV effectively delivered in a low dosing frequency, GNP-gp91 eyedrops provides an alternative strategy for clinical ocular disease treatment in the culture.

Sunitinib malate-loaded biodegradable microspheres for the prevention of corneal neovascularization in rats

Liposomal sunitinib for ocular drug delivery: A potential treatment for choroidal neovascularization

An Active Transport Dual Adaptive Nanocarrier Designed to Overcome the Corneal Microenvironment for Neovascularization Therapy.

A SU6668 pure nanoparticle-based eyedrops: toward its high drug Accumulation and Long-time treatment for corneal neovascularization

Development of injectable hyaluronic acid-based hydrogels with antioxidant activity for the treatment of corneal neovascularization

Dasatinib Loaded Nanostructured Lipid Carriers for Effective Treatment of Corneal Neovascularization

Dasatinib and erianin co-loaded ion-responsive in-situ hydrogel for effective treatment of corneal neovascularization

Biomimetic Nanocomplex Based Corneal Neovascularization Theranostics.

A Synergistic Therapy with Antioxidant and Anti-VEGF: Toward Its Safe and Effective Elimination for Corneal Neovascularization

Inhibiting Corneal Neovascularization by Sustainably Releasing Anti-Vegf and Anti-Inflammation Drugs from Silica-Thermogel Nanohybrids

Ocular delivery of sunitinib-loaded nanoparticles doped in tragacanthic acid hydrogel in treatment of diabetic retinopathy in rats

Bioadhesive glycosylated nanoformulations for extended trans-corneal drug delivery to suppress corneal neovascularization

Minocycline-loaded nHAP/PLGA microspheres for prevention of injury-related corneal angiogenesis

Co-delivery of metformin and levofloxacin hydrochloride using biodegradable thermosensitive hydrogel for the treatment of corneal neovascularization

Combination Nanomedicine Strategy for Preventing High-Risk Corneal Transplantation Rejection

Antiangiogenic Nanomicelles for the Topical Delivery of Aflibercept to Treat Retinal Neovascular Disease

Functional Peptide-Loaded Gelatin Nanoparticles as Eyedrops for Cornea Neovascularization Treatment

Innovative platelet-derived extracellular vesicle drug delivery system for the treatment of corneal neovascularization

Clickable Corneal Neovascularization Therapy with ROS-Responsive Polydopamine Silica Nanoparticles Loaded with Fenofibrate

Sunitinib-Loaded Chondroitin Sulfate Hydrogels as a Novel Drug-Delivery Mechanism for the Treatment of Pancreatic Neuroendocrine Tumors

In vitro and in vivo studies of ocular topically administered NLC for the treatment of uveal melanoma